Pacira BioSciences, Inc. filed Post-Effective Amendments to thirteen Form S-8 registration statements on November 17, 2026, deregistering all remaining unsold shares under those plans following the company's merger with Viatris Inc.
Key Highlights
- Merger completed November 17, 2026: Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., merged with and into Pacira BioSciences, leaving Pacira as a wholly owned subsidiary of Viatris.
- Thirteen registration statements terminated: Post-effective amendments cover Registration Nos. 333-175101 through 333-297971, spanning equity and employee stock purchase plans filed from 2011 to 2026.
- All remaining unsold shares deregistered: According to the filing, after giving effect to the amendments, there will be no remaining shares registered by the company pursuant to the Registration Statements.
- Merger Agreement dated October 8, 2026: The transaction was governed by an Agreement and Plan of Merger among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc.
- Common stock par value $0.001 per share: The deregistered securities are shares of Pacira BioSciences common stock held across multiple equity compensation plans, including the Amended and Restated 2011 Stock Incentive Plan and the Amended and Restated 2014 Employee Stock Purchase Plan.
- Registrant classified as large accelerated filer: The filing identifies Pacira BioSciences as a large accelerated filer incorporated in Delaware, with principal offices at 2000 Sierra Point Parkway, Suite 900, Brisbane, California.
Pacira BioSciences Closes Out Equity Plans as Viatris Merger Takes Effect
Pacira BioSciences, Inc. (NASDAQ:PCRX), a Delaware pharmaceutical company headquartered in Brisbane, California, filed these post-effective amendments as a direct consequence of the merger completed on November 17, 2026. Under the Merger Agreement signed October 8, 2026, Viatris Inc. structured the transaction through its wholly owned subsidiary, Peach Purchaser Sub Inc., which merged into Pacira BioSciences. The company now continues as a wholly owned subsidiary of Viatris, according to the filing.
The post-effective amendments collectively address thirteen Form S-8 registration statements that Pacira BioSciences and its predecessor, Pacira Pharmaceuticals, Inc., filed with the SEC between June 2011 and August 2026. Those statements had registered shares under multiple equity compensation arrangements, including the Pacira Pharmaceuticals, Inc. 2007 Stock Option/Stock Issuance Plan, the Amended and Restated 2011 Stock Incentive Plan, the Amended and Restated 2014 Employee Stock Purchase Plan, and the Amended and Restated 2014 Inducement Plan. The share counts registered under individual statements ranged from 175,000 shares to 4,000,000 shares, as detailed in the filing.
The filing states that the registrant "has terminated all offerings and sales pursuant to the Registration Statements" as a result of the Merger Agreement's terms. The amendments fulfill an undertaking Pacira BioSciences made when it originally filed each registration statement, committing to remove unsold shares from registration by post-effective amendment upon termination of offerings. President Michael Rainerman signed the amendments on behalf of the company, and the filing notes that under Rule 478 of the Securities Act of 1933 no additional signatories are required.
What Was Disclosed
Pacira BioSciences filed thirteen post-effective S-8 amendments on November 17, 2026, to deregister all unsold shares under its historical equity compensation plans, citing the completion of its merger with Viatris Inc. as the triggering event under the October 8, 2026 Merger Agreement.




Please wait processing your request...